XML 59 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 9 - Share-based Compensation (Details Textual)
$ / shares in Units, $ in Millions
9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
$ / shares
shares
Dec. 31, 2021
Dec. 31, 2020
Number Of Active Stock Incentive Plans 1      
Number Of Inactive Stock Incentive Plans 1      
Performance Shares [Member]        
Performance Share Award Target Level, Percentage 100.00%      
Performance Awards Issued Multiplier     93.00% 141.00%
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number At Target Level Of Performance (in shares) 149,000      
Performance Shares [Member] | Minimum [Member]        
Performance Awards Issued Multiplier 0.00%      
Performance Shares [Member] | Maximum [Member]        
Performance Awards Issued Multiplier 200.00%      
Restricted Stock Units and Performance Stock Awards [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $ $ 4.6      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) 1 year 7 months 6 days      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) [1] 116,622      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares $ 30.68      
Stock Awards [Member] | Director [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 11,380 12,606    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares $ 30.75 $ 30.94    
[1] The number of PSAs disclosed in this table are at the target level of 100%.